Polyrizon Bolsa (NASDAQ: PLRZ) cotización, noticias, gráficos, investigación bursátil, perfil.

Polyrizon (NASDAQ:PLRZ) Bolsa Cotizaciones y resumen de noticias

Polyrizon

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

Polyrizon Ltd

Biotech

News

General

IRIX

Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.

<h3>Gainers</h3>
<ul>
<li>Worthington Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) stock moved upwards by 16.1% to $44.37 during Wednesday's pre-market session. The company's market cap stands at $2.2 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) shares rose 12.65% to $1.78. The company's market cap stands at $22.4 million. </li>
<li>Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) shares moved upwards by 12.46% to $3.7. The company's market cap stands at $39.9 million. </li>
<li>Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) shares increased by 12.15% to $7.75. The market value of their outstanding shares is at $808.8 million. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock increased by 9.57% to $0.79. The market value of their outstanding shares is at $2.0 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) stock moved upwards by 9.57% to $1.6. The company's market cap stands at $14.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fitell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) stock decreased by 27.0% to $28.01 during Wednesday's pre-market session. The market value of their outstanding shares is at $563.1 million. </li>
<li>XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) shares decreased by 9.45% to $1.62. The company's market cap stands at $8.5 million. </li>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares fell 8.53% to $0.08. The company's market cap stands at $1.4 million. </li>
<li>Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares decreased by 7.62% to $12.86. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) stock declined by 7.6% to $2.31. The company's market cap stands at $2.6 million. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 5.61% to $1.18. The company's market cap stands at $12.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CANG

EZGO

FTEL

HSAI

ISPO

JZXN

LXEH

RIME

VNCE

XWEL

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

SVRA

Savara Initiates Rolling Submission Of Biologics License Application To FDA For MOLBREEVI In Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis

Contracts

Parsons Announced It Has Been Awarded $20 Million U.S. Army Corps of Engineers Contract for Puerto Rico Microgrid

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 148.4% to $1.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $46.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 140.95% to $2.53. The company's market cap stands at $10.6 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock increased by 68.18% to $0.79. The company's market cap stands at $6.4 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 44.02% to $0.09. The company's market cap stands at $13.2 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares increased by 22.79% to $0.41. The company's market cap stands at $76.6 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares rose 18.09% to $1.13. The company's market cap stands at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 34.8% to $0.33 during Wednesday's pre-market session. The company's market cap stands at $3.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 33.5% to $4.2. The market value of their outstanding shares is at $2.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock fell 31.53% to $5.06. The market value of their outstanding shares is at $325.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares declined by 23.32% to $0.32. The market value of their outstanding shares is at $4.4 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 21.66% to $3.51. The company's market cap stands at $7.6 billion. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) stock fell 20.53% to $11.0. The company's market cap stands at $461.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

CGTX

CRVS

EVAX

NIVF

PLRZ

PTPI

RADX

RNAZ

SIBN

TCBP

TNXP

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock moved upwards by 83.1% to $2.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $71.3 million. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) stock moved upwards by 32.81% to $0.3. The market value of their outstanding shares is at $4.8 million. </li>
<li>Richtech Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) shares rose 21.91% to $1.5. The market value of their outstanding shares is at $142.1 million. </li>
<li>Ming Shing Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSW#NASDAQ">MSW</a>) shares moved upwards by 17.68% to $5.79. The market value of their outstanding shares is at $75.1 million. </li>
<li>Hyzon Motors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) shares rose 13.07% to $1.9. The company's market cap stands at $14.4 million. </li>
<li>Greenwave Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) stock increased by 12.58% to $0.72. The market value of their outstanding shares is at $16.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) stock declined by 16.6% to $3.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $17.4 million. </li>
<li>Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) stock decreased by 11.79% to $4.94. The market value of their outstanding shares is at $42.9 million. </li>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) stock declined by 10.63% to $4.22. The market value of their outstanding shares is at $89.2 million. </li>
<li>Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) stock fell 9.49% to $77.22. The market value of their outstanding shares is at $8.0 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Mesa Air Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) shares decreased by 9.17% to $1.09. The market value of their outstanding shares is at $45.0 million. </li>
<li>ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) stock declined by 8.58% to $50.2. The market value of their outstanding shares is at $3.1 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EFSH

GWAV

HUHU

HYZN

MESA

SIDU

SYNX

VSTE

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) stock rose 24.5% to $1.98 during Wednesday's pre-market session. The market value of their outstanding shares is at $35.9 million. </li>
<li>CommScope Hldg Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) stock moved upwards by 21.21% to $6.8. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock increased by 20.82% to $0.8. The market value of their outstanding shares is at $22.5 million. </li>
<li>Netgear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares increased by 18.57% to $30.45. The company's market cap stands at $885.2 million. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares increased by 15.36% to $19.37. The market value of their outstanding shares is at $2.3 billion. </li>
<li>WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) stock increased by 13.93% to $1.39. The market value of their outstanding shares is at $135.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) stock decreased by 12.8% to $3.08 during Wednesday's pre-market session. The company's market cap stands at $112.9 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares fell 11.35% to $1.25. The market value of their outstanding shares is at $37.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock declined by 9.0% to $0.91. </li>
<li>AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) shares declined by 6.9% to $5.4. The market value of their outstanding shares is at $58.9 million. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) stock declined by 6.05% to $2.8. The company's market cap stands at $181.0 million. </li>
<li>IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) stock fell 5.89% to $41.26. The market value of their outstanding shares is at $8.8 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AUID

CMBM

COMM

IONQ

LAES

LDTC

MAPS

NTGR

OPTX

QUBT

SOBR

VRAR

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.53 by 3.77 percent. This is a 6.78 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $970.40 million which beat the analyst consensus estimate of $959.70 million by 1.11 percent. This is a 2.20 percent increase over sales of $949.50 million the same period last year.

Earnings

Earnings Beats

MLKN

MillerKnoll Q2 Adj $0.55 Beats $0.53 Estimate, Sales $970.40M Beat $959.70M Estimate

A new analyst report that looks at downloads and user data could show the winners and losers and what's ahead for<a href="https://www.benzinga.com/topic/streaming"> the streaming sector.</a>
The Media and Internet Report: JPMorgan analysts led by David Karnovsky released a report on streaming downloads and user data using data from Sensor Tower, the iOS App Store and Google Play.
"Results in November were generally positive, with global downloads and DAUs mostly up on a sequential basis," the analyst report said.
Here's a look at some of the companies highlighted in the report.
The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>): Disney+ downloads were down 6% month-over-month in November, which marked an improvement after two straight months of double-digit declines. The premiere of "Deadpool &amp; Wolverine" on the platform was the key release and may have led to some of the improved figures. The analyst said December includes the premieres of "Star Wars: Skeleton Crew," "Dream Productions" and "Doctor Who: Joy to the World." The ESPN tile being added to Disney+ could also help boost usage on the streaming platform, the analyst said, with some sports content available to Disney+ users without having a subscription.
"We think this is a positive step for the service and should boost overall engagement while potentially creating a new audience," the report noted.
Hulu, which is majority owned by Disney, saw downloads drop 5% month-over-month in November and daily active users fall 1% month-over-month, which came after two straight months of increases.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42537187/christmas-movie-with-the-rock-flops-at-box-office-breaks-streaming-records-for-this-company">Christmas Movie With The Rock Flops At Box Office, Breaks Streaming Records For This Company</a>
Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>): The media company is highlighted as a winner in the report with Paramount+ global downloads up 32% month-over-month in November, marking the platform's largest sequential gain since February 2024. The premiere of "Landman" and "The Agency" may have contributed to the gains. "Landman" was the biggest series launch on Paramount+ in two years according to the report.
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>): Global downloads were up 14% year-over-year in November, an improvement from a -2% year-over-year decline in November. The increase may have been attributed by new content that included the Jake Paul vs. Mike Tyson live boxing event. The figures could get even better for the month of December.
"We believe content builds into year-end and 2025," the report said.
The report also cites several new movies and series along with the highly anticipated return of "Squid Game" and two NFL games on Christmas Day.
Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): Streaming platform Prime Video saw downloads down 7% year-over-year and daily active users down 8% year-over-year. The analysts expect a strong December for the platform with the premiere of "Beast Games" on Dec. 19 and several other series.
Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): Streaming platform Peacock saw November downloads up 31% month-over-month, which may have been thanks to 2024 election day coverage and the debut of "Twisters" during the month. A Black Friday special of $19.99 per year for Peacock may have also attributed to the better numbers, the analyst said.
Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>): Max downloads were up 20% month-over-month in November, with the launch of the streaming platform in Indonesia, Malaysia, Philippines, Singapore, Thailand, Taiwan and Hong Kong the likely reason. Downloads were down 5% month-over-month for the United States and Canada and up 29% in the other territories. Daily active users and monthly active users were also up month-over-month, including in the United States and Canada region.
Why It's Important: Based on the findings of the report, Paramount+ and Max are singled out as having strong Novembers. Prime Video and Netflix could be set for strong Decembers thanks to the release of "Beast Games" for Amazon and "Squid Game" and NFL games for Netflix.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/42199235/amazon-prime-vs-netflix-mrbeast-game-show-arrives-dec-19-squid-game-season-2-drops-1-week-later">Amazon Prime Vs. Netflix: MrBeast Game Show Arrives Dec. 19, &#8216;Squid Game&#8217; Season 2 Drops 1 Week Later</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Entertainment

Analyst Ratings

Trading Ideas

AMZN

CMCSA

NFLX

PARA

PARAA

Streamers Max, Paramount+ Won November: Here's Why Analyst Expects Netflix, Amazon To Win December

Offerings

QNCX

Quince Therapeutics Files For Mixed Shelf Offering Of Up To $200M

Management

ADSK

Autodesk Names John Cahill And Ram Krishnan To Join Board Effective Immediately; Lorrie Norrington Informs Her Intention Not To Stand For Re-election At 2025 Annual General Meeting

WIIM

Micron shares are trading lower following a Q1 revenue miss and weak Q2 guidance.

Guidance

Micron Sees Q2 Revenue $7.7B-$8.1B vs $9.00B Est; Adj. EPS $1.33-$1.53 vs $1.92 Est

PLTR

Palantir Extends Long-standing Partnership With US Army To Deliver Army Vantage Capability In Support Of Army Data Platform; Total Value Of Agreement Is $400.74M For Period Of Up To Four Years, With Total Available Ceiling Of $618.87M

<ul>
<li>Breakthrough provides the first-ever certificates of authenticity and compliance for independent verification of AI training, inference, and benchmarks at runtime.</li>
<li>The solution delivers on-silicon, real-time governance — an industry-first created from two years of intensive research joined by advisors at Stanford and MIT.</li>
<li>Delivered this month to first clients with transformative applications across the life sciences, public sector, finance, and media to certify smarter, safer AI systems and agents.</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.eqtylab.io%2F&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=EQTY+Lab&amp;index=1&amp;md5=c10a00935d9dd60e9565ee82b154c342">EQTY Lab</a>, in collaboration with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.intel.com%2Fcontent%2Fwww%2Fus%2Fen%2Fhomepage.html&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=Intel&amp;index=2&amp;md5=f77b88357a53a6279a5450ba2839b0c5">Intel</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2F&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=NVIDIA&amp;index=3&amp;md5=ea11821b4ed59a27d1588b10ea5483af">NVIDIA</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), announced today the release of the Verifiable Compute AI framework, the first hardware-based solution to govern and audit AI workflows. Verifiable Compute represents a significant leap forward in ensuring that AI is explainable, accountable, and secure at runtime. It gives consumers and businesses new confidence to accelerate AI adoption and development.

INTC

NVDA

EQTY Lab, In Collaboration With Intel And NVIDIA Announces The Release Of The Verifiable Compute AI Framework, The First Hardware-Based Solution To Govern And Audit AI Workflows

Micron Technology Q1 2025 Adj. EPS $1.79 Beats $1.76 Estimate, Sales $8.709 Miss $8.721B Estimate

Throughout the last three months, 8 analysts have evaluated Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.38, with a high estimate of $64.00 and a low estimate of $37.00. Highlighting a 10.51% decrease, the current average has fallen from the previous average price target of $50.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1734555665_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Noble Corp among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Nikhil Gupta</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Noble Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Noble Corp compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Noble Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Noble Corp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Noble Corp analyst ratings.</a>
<h2>Get to Know Noble Corp Better</h2>
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.
<h3>Noble Corp: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Noble Corp displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 14.78%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Noble Corp's net margin excels beyond industry benchmarks, reaching 7.65%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Noble Corp's ROE stands out, surpassing industry averages. With an impressive ROE of 1.41%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Noble Corp's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: Noble Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 8 Analysts Discuss Noble Corp Stock

Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $48.0, a high estimate of $52.00, and a low estimate of $41.00. This upward trend is evident, with the current average reflecting a 2.67% increase from the previous average price target of $46.75.
<img src="https://www.benzinga.com/files/images/story/2024/1734555657_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Brighthouse Finl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Brighthouse Finl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Brighthouse Finl compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Brighthouse Finl's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Brighthouse Finl's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BHF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Brighthouse Finl analyst ratings.</a>
<h2>About Brighthouse Finl</h2>
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, and Run-off. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
<h3>A Deep Dive into Brighthouse Finl's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Brighthouse Finl's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 75.74%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Brighthouse Finl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.64%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Brighthouse Finl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.1% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Brighthouse Finl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.06%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Brighthouse Finl's debt-to-equity ratio is below the industry average at 0.57, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Brighthouse Financial, Inc. - Common Stock

Brighthouse Finl Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

In the preceding three months, 18 analysts have released ratings for Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $507.22, a high estimate of $600.00, and a low estimate of $465.00. This upward trend is apparent, with the current average reflecting a 0.92% increase from the previous average price target of $502.61.
<img src="https://www.benzinga.com/files/images/story/2024/1734555647_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Microsoft. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$515.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$525.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$510.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$465.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$475.00</td>
<td>$495.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$470.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$548.00</td>
<td>$506.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Mark Moerdler</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$501.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$497.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$505.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$470.00</td>
<td>$485.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$475.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Microsoft. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Microsoft compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Microsoft's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Microsoft's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MSFT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Microsoft analyst ratings.</a>
<h2>Delving into Microsoft's Background</h2>
Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).
<h3>Microsoft's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Microsoft showcased positive performance, achieving a revenue growth rate of 16.04% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Microsoft's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 37.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Microsoft's ROE excels beyond industry benchmarks, reaching 8.87%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.77%, the company showcases effective utilization of assets.
Debt Management: Microsoft's debt-to-equity ratio is below the industry average at 0.21, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MSFT

Microsoft Stock: A Deep Dive Into Analyst Perspectives (18 Ratings)

29 analysts have expressed a variety of opinions on MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">13</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">10</td>
<td align="right">12</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for MongoDB, presenting an average target of $379.66, a high estimate of $430.00, and a low estimate of $220.00. Witnessing a positive shift, the current average has risen by 10.35% from the previous average price target of $344.04.
<img src="https://www.benzinga.com/files/images/story/2024/1734555630_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of MongoDB by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Announces</td>
<td>Buy</td>
<td>$350.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Sell</td>
<td>$220.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Koenig</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Neutral</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$425.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$405.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$350.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Matthew Broome</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$360.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$345.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$330.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MongoDB. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MongoDB compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of MongoDB's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of MongoDB's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MongoDB analyst ratings.</a>
<h2>Get to Know MongoDB Better</h2>
Founded in 2007, MongoDB is a document-oriented database. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
<h3>Financial Insights: MongoDB</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: MongoDB's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately 22.27%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: MongoDB's net margin is impressive, surpassing industry averages. With a net margin of -1.85%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): MongoDB's ROE stands out, surpassing industry averages. With an impressive ROE of -0.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): MongoDB's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.31% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.77, MongoDB adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where MongoDB Stands With Analysts

The deal size was increased to 959K shares of common stock from 808K shares of common stock and the range was $4.38-$6.02. Aegis acted as sole book...

Polyrizon 959K share IPO priced at $4.38

Polyrizon (PLRZ) priced 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share a...

Polyrizon opens at $1.64, IPO priced at $4.38 per unit

Polyrizon and Gelteq made their public debut on Tuesday in a quiet Halloween week for the IPO market. LATEST IPOS AND DIRECT LISTINGS: Polyrizon (P...

Opening Day: Polyrizon, Gelteq debut in quiet IPO week

Heritage Distilling, Ming Shing and Dynamix made their public debut as the IPO market cools off ahead of Thanksgiving week in the U.S. LATEST IPOS ...

Opening Day: Heritage Distilling, Dynamix open for trading

Heritage Distilling, Ming Shing, and Dynamix all made a public debut as the IPO market has cooled off ahead of Thanksgiving week in the U.S.

Heritage Distilling, Dynamix Open For Trading

The company states: "Polyrizon (PLRZ) Ltd. announces the signing of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a leading E...

Polyrizon enters into manufacturing pact for CTM supply of PL-14 allergy blocker

Polyrizon (PLRZ) previously announced that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a leading European-based G...

Polyrizon agreement with Eurofins secures CTM for PL-14 allergy blocker trial

ADBE

CAMP

CASK

CBLL

CLIK

DYNX

GELS

SKYQ

STFS

IPOs

Press Releases

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker "PLRZ"

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Health Care

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Aditxt

180 Life Sciences

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Moleculin Biotech

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

PolyRizon shares are trading higher after the company announced it secured a GMP partnership with Eurofins CDO Amatsiaquitaine.

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Discover the 10 best cryptocurrencies to invest in for November 2024. Stay ahead in the crypto market with our expert insights and analysis! Learn more now!

10 Best Cryptocurrencies to Invest In for December 2024

10 Best Cryptocurrencies to Invest in for November 2024

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Cryptocurrency

Markets

$BTC

$DOGE

$ETH

Bitcoin, Ethereum, Dogecoin Stay Muted Before Fed's Interest Rate Decision: Analyst Says BTC In Parabolic Phase, Reveals Its Duration

$PEPE

$SHIB

Dogecoin Down Another 4% As Sentiment Sours: What Is Going On?

$SOL

Mark Cuban Expresses Sympathy For 'Hawk Tuah' Girl Amid Meme Coin Controversy: 'Wasn't Something She Fully Understood'

Trump Inauguration Could Coincide With A 'Harrowing Dump' For Crypto, Arthur Hayes Warns

Pudgy Penguin Token Launches At $2 Billion Valuation, Could Land 'Between Shiba Inu And Dogecoin,' Trader Says

Future Finance Newsletter

acf/page-sidebar-placement

Cryptocurrency /Money Sidebar

Apertura	$2.48
Cierre	-
Volumen / Prom.	136.08M / 556.59K
Rango diario	$2.41 - $4.80
Rango de 52 semanas	0.77 - 1.97
Capitalización bursátil	$11.74M
Ratio PER	-
Rentabilidad por dividendo	-
Exchange	NASDAQ
RSI	82
Interés en corto	0.89%
Días para cubrir	1

Apertura	$2.48
Cierre	-
Volumen / Prom.	136.08M / 556.59K
Rango diario	$2.41 - $4.80
Rango de 52 semanas	0.77 - 1.97
Capitalización bursátil	$11.74M
Ratio PER	-
Rentabilidad por dividendo	-
Exchange	NASDAQ
RSI	82
Interés en corto	0.89%
Días para cubrir	1

Comments

Polyrizon

Polyrizon (PLRZ) Previsión

Polyrizon (NASDAQ:PLRZ) Bolsa Cotizaciones y resumen de noticias

Noticias recientes

Finanzas

Comparar

PREGUNTAS FRECUENTES

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Nombre

Ingresos Variación
Bruto Variación
EBITDA Variación
EBIT Variación
Beneficios Variación